Longevity & AgingFour Alzheimer's Innovators Set to Reshape Brain Aging at AAIC 2026
At the Alzheimer's Association International Conference 2026 in London, four companies are presenting data that push beyond the dominant amyloid-targeting approach. Cognito Therapeutics is showcasing a wearable device using light and sound to stimulate the brain at home, with new biomarker data suggesting effects on brain lipid transport proteins. Biogen is presenting Phase 2 results for a tau-reducing drug alongside real-world data on its approved therapy LEQEMBI. Eisai, Biogen's collaborator, brings over 50 presentations covering treatment, diagnosis, and patient care. Together, these developments signal that Alzheimer's care is evolving toward a multi-strategy approach targeting different biological drivers of the disease simultaneously.
